Patient characteristics at the time of presentation for historical non-caplacizumab cohort vs caplacizumab cohort
| . | Non-caplacizumab cohort (n = 16), median (range) . | Caplacizumab cohort (n = 17), median (range) . | P value . |
|---|---|---|---|
| Female, n (%) | 14 (87.5) | 10 (58.8) | .07 |
| Age, y | 50.4 (23.5-69.3) | 47.1 (19.8-85.3) | .68 |
| Race, n (%) | — | — | .06 |
| Black | 13 (81.2) | 11 (65) | .29 |
| White | 1 (6.2) | 6 (35) | .04 |
| Asian | 2 (12.5) | 0 | .13 |
| Presenting episode, n (%) | .61 | ||
| Initial | 12 (75) | 14 (82.4) | |
| Recurrent | 4 (25) | 3 (17.6) | |
| Platelet count, × 109/L | 18.5 (6-147) | 10 (5-53) | .14 |
| ADAMTS13 activity, IU/dL | 5 (<1-9) | <1 | <.001 |
| ADAMTS13 antibody, U/mL | 34 (7-68; n = 8) | 45 (1-104; n = 17) | .44 |
| Neurologic symptoms at presentation,∗ n (%) | 10 (62.5) | 13 (76.5) | .4 |
| . | Non-caplacizumab cohort (n = 16), median (range) . | Caplacizumab cohort (n = 17), median (range) . | P value . |
|---|---|---|---|
| Female, n (%) | 14 (87.5) | 10 (58.8) | .07 |
| Age, y | 50.4 (23.5-69.3) | 47.1 (19.8-85.3) | .68 |
| Race, n (%) | — | — | .06 |
| Black | 13 (81.2) | 11 (65) | .29 |
| White | 1 (6.2) | 6 (35) | .04 |
| Asian | 2 (12.5) | 0 | .13 |
| Presenting episode, n (%) | .61 | ||
| Initial | 12 (75) | 14 (82.4) | |
| Recurrent | 4 (25) | 3 (17.6) | |
| Platelet count, × 109/L | 18.5 (6-147) | 10 (5-53) | .14 |
| ADAMTS13 activity, IU/dL | 5 (<1-9) | <1 | <.001 |
| ADAMTS13 antibody, U/mL | 34 (7-68; n = 8) | 45 (1-104; n = 17) | .44 |
| Neurologic symptoms at presentation,∗ n (%) | 10 (62.5) | 13 (76.5) | .4 |
Neurologic symptoms include headache, confusion, ataxia, seizures, altered mental status, and focal abnormalities.